Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
A specific bremelanotide product, Vyleesi, is FDA-approved for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women
More in Science & Research Peptide Clinical Evidence in 2026: How to Separate Signal from Hype A practical guide to reading peptide research in 2026: trial design, evidence levels, safety signals, regulatory context, and what to track
Many patients report improvements in sleep depth and nighttime recovery
Emerging evidence suggests a favorable influence on lipid profiles
What sets GHK-Cu apart in the research literature is scale: naturally occurring levels of the peptide in human plasma decline from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, a drop researchers have used as a starting point for studying its potential connection to age-related changes in tissue repair
US$ 21.30
US$ 28.12
US$ 24.92
US$ 23.75
.png)
US$ 28.52
US$ 23.86
US$ 25.79
US$ 26.17
